71335-2974 Ondansetron

Product NDC:

71335-2974

Brand Name:

Ondansetron

Generic Name:

Ondansetron

Dosage Form Name:

TABLET, ORALLY DISINTEGRATING

Administration Route:

Oral

Substances:

Name: ONDANSETRON

Strength: 8.0

Unit: mg/1

Packages:

Code: 71335-2974-01

Description: 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-1)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-02

Description: 10 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-2)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-03

Description: 9 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-3)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-04

Description: 5 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-4)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-05

Description: 3 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-5)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-06

Description: 6 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-6)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-07

Description: 12 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-7)

Effective Date: Nov. 6, 2025

Discontinued:

Code: 71335-2974-08

Description: 4 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (71335-2974-8)

Effective Date: Nov. 6, 2025

Discontinued:

SEER*Rx Category:

Ancillary Therapy

Major Class:

Antiemetic

Minor Class:

5HT3 Receptor Antagonist

Orphan Drug Designation:

Status:

In Use

CanMED and the Oncology Toolbox

CanMED: NDC